BioLineRx (BLRX) Intangibles (2011 - 2026)

BioLineRx's Intangibles history runs 15 years deep, the most recent figure standing at $16.4 million for Q4 2025.

• In Q4 2025, Intangibles rose 56.65% year-over-year to $16.4 million; the TTM figure through Dec 2025 stood at $16.4 million (up 56.65% YoY), while the FY2025 annual figure was $16.4 million, up 56.65% from the prior year.
• Intangibles for Q4 2025 stood at $16.4 million, up from $10.4 million in the prior quarter.
• The five-year high for Intangibles was $22.6 million in Q4 2022, with the low at $10.4 million in Q3 2025.
• The 5-year median for Intangibles is $21.7 million (2021), against an average of $18.1 million.
• The sharpest annual moves came in 2024 and 2025: Intangibles tumbled 53.19% in 2024, then jumped 56.65% in 2025.
• BioLineRx's Intangibles stood at $21.7 million in 2021, then increased by 4.1% to $22.6 million in 2022, then decreased by 1.19% to $22.3 million in 2023, then plunged by 53.19% to $10.4 million in 2024, then surged by 56.65% to $16.4 million in 2025.
• Business Quant data shows BLRX's Intangibles at $16.4 million in Q4 2025, $10.4 million in Q3 2025, and $10.4 million in Q2 2025.